Senti Bio Announces Reverse Stock Split
Senti Biosciences (Nasdaq: SNTI) has announced a 1-for-10 reverse stock split effective July 17, 2024, at 11:59 p.m. EDT. Trading on a split-adjusted basis will begin on July 18, 2024. This move will reduce outstanding shares from approximately 45.8 million to 4.6 million. The reverse split aims to address Nasdaq's minimum bid price requirement of $1.00 per share, which SNTI has not met since August 2023. Senti Bio has until August 5, 2024, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. The company believes this action will increase its stock price and resolve the compliance issue.
- Potential to regain Nasdaq compliance and avoid delisting
- Possible increase in stock price due to reverse split
- Reduction in total number of outstanding shares
- Risk of not meeting Nasdaq's minimum bid price requirement despite the reverse split
- Potential dilution of shareholder value
Reverse stock splits often raise concerns among investors as they can signal financial difficulties within a company. While they don't change the underlying value of the company, they reduce the number of shares outstanding, which in this case drops from approximately 45.8 million to about 4.6 million.
One immediate impact is on share price and liquidity. By multiplying the current share price by 10, Senti Bio aims to meet the Nasdaq's minimum bid price requirement of $1.00 per share. However, reverse splits can often be followed by price declines as the market perceives them negatively. The reduced number of shares can also reduce liquidity, making it harder for investors to buy or sell shares without affecting the price.
This move is essentially a compliance measure to maintain listing on Nasdaq, which is critical for access to capital and investor confidence. However, it does not address the underlying operational or financial challenges. Investors should carefully consider these factors and monitor the company's ability to sustain any potential price increase post-split.
The decision to transfer Senti Bio's listing from The Nasdaq Global Market to The Nasdaq Capital Market is notable. The Nasdaq Global Market typically hosts larger, more established companies with higher listing standards. Moving to the Capital Market, which caters to smaller companies, indicates that Senti Bio is facing challenges in meeting the stringent requirements of its previous tier.
Another important point is that the company's ongoing struggle to meet the $1.00 minimum bid price requirement reflects broader market sentiment and potential issues with demand for its stock. This can result in reduced investor confidence and a narrower pool of potential investors.
While the reverse stock split may temporarily boost the stock price, it’s more a cosmetic adjustment than a fundamental improvement. Investors should be cautious and look for any real operational changes or growth initiatives that could drive long-term value.
Shares expected to begin trading on split-adjusted basis on July 18, 2024
SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”) , a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that its Board of Directors has determined to effect a one-for-ten (1-for-10) reverse stock split of Senti Bio’s common stock, par value
The reverse stock split will take effect at 11:59 p.m. EDT on July 17, 2024, and Senti Bio’s common stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market as of the opening of trading on July 18, 2024. The CUSIP number of 81726A209 will be assigned to Senti Bio’s common stock when the reverse stock split becomes effective.
When the reverse stock split becomes effective, every ten (10) of Senti Bio’s issued shares of common stock will be combined into one issued share of common stock, without any change to the par value per share. This will reduce the number of outstanding shares of common stock from approximately 45.8 million shares to approximately 4.6 million shares.
No fractional shares will be issued in connection with the reverse stock split. Stockholders who would otherwise hold a fraction of a share of common stock of Senti Bio will receive a cash payment in lieu thereof at a price equal to that fraction of a share to which the stockholder would otherwise be entitled, multiplied by the closing price of Senti Bio’s common stock on Nasdaq on July 17, 2024 (as adjusted for the reverse split).
Stockholders with shares held in book-entry form or through a bank, broker, or other nominee are not required to take any action and will see the consequence of the reverse stock split reflected in their accounts on or after July 18, 2024. Such beneficial holders may contact their bank, broker, or nominee for more information.
The reverse stock split ratio approved by the Board of Directors is within the previously disclosed range of ratios for a reverse stock split authorized by the stockholders of Senti Bio at the 2024 Annual Meeting of Stockholders of Senti Bio.
As previously announced, on August 7, 2023, the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notified Senti Bio that the bid price for Senti Bio’s common stock had closed below
About Senti Bio
Senti Bio is a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging a synthetic biology platform called Gene Circuits to create therapies with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, spare healthy cells, increase specificity to target cells and control the expression of drugs even after administration. Senti Bio’s wholly-owned pipeline utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells, outfitted with Gene Circuits, to target challenging liquid and solid tumor indications. Senti Bio has also preclinically demonstrated the potential breadth Gene Circuits in other modalities, diseases outside of oncology, and continues to advance these capabilities through partnerships with Spark Therapeutics and BlueRock Therapeutics.
Forward-Looking Statements
This press release contains certain statements that are not historical facts and are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended including statements with respect to Senti Bio’s ability to regain compliance with Nasdaq’s continued listing standards and remain listed on Nasdaq or any other major stock exchange and other statements that are forward looking. These forward-looking statements generally are identified by the words “believe,” “could,” “predict,” “continue,” “ongoing,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” “forecast,” “seek,” “target” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations of Senti Bio’s management and assumptions, whether or not identified in this document, and, as a result, are subject to risks and uncertainties. Forward-looking statements include, but are not limited to, the anticipated trading price of Senti Bio’s common stock following the reverse stock split, Senti Bio’s anticipated receivables under its agreements with GeneFab; expectations regarding its growth, strategy, progress and timing of its clinical trials, including the anticipated dosing of patients and availability of data, and the timing thereof; the ability to initiate new clinical programs; as well as statements about the potential attributes and benefits of Senti Bio’s platform technology and the progress and continuation of its collaborations with Celest, Spark Therapeutics and BlueRock Therapeutics and other collaboration and strategic partners. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as, a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Senti Bio. Many factors could cause actual future results to differ materially from the forward-looking statements in this document, including but not limited to: (i) changes in domestic and foreign business, market, financial, political and legal conditions, (ii) changes in the competitive and highly regulated industries in which Senti Bio operates, variations in operating performance across competitors, changes in laws and regulations affecting Senti Bio’s business, (iii) the ability to implement business plans, forecasts and other expectations, (iv) the risk of downturns and a changing regulatory landscape in Senti Bio’s highly competitive industry, (v) risks relating to the uncertainty of any projected financial information with respect to Senti Bio, (vi) risks related to uncertainty in the timing or results of Senti Bio’s clinical trial start up, clinical studies, patient enrollment, and GMP manufacturing startup activities, (vii) Senti Bio’s dependence on third parties in connection with clinical trial startup, clinical studies, and GMP manufacturing activities, (viii) risks related to delays and other impacts from macroeconomic and geopolitical events, increasing rates of inflation and rising interest rates on business operations, and (ix) the success of any future research and development efforts by Senti Bio. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Senti Bio’s Annual Report on Form 10-K, filed with the SEC on March 21, 2024, and other documents filed by Senti Bio from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements in this document. There may be additional risks that Senti Bio does not presently know, or that Senti Bio currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements in this document. Forward-looking statements speak only as of the date they are made. Senti Bio anticipates that subsequent events and developments may cause Senti Bio’s assessments to change. Except as required by law, Senti Bio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.
Availability of Other Information About Senti Biosciences, Inc.
For more information, please visit the Senti Bio website at https://www.sentibio.com or follow Senti Bio on X (@SentiBio) and LinkedIn (Senti Biosciences). Investors and others should note that we communicate with our investors and the public using our company website (www.sentibio.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on Twitter and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
FAQ
What is the reverse stock split ratio for Senti Biosciences (SNTI)?
When will SNTI stock begin trading on a split-adjusted basis?
How many outstanding shares will SNTI have after the reverse split?
Why is Senti Biosciences (SNTI) implementing a reverse stock split?
What is the deadline for Senti Biosciences (SNTI) to regain Nasdaq compliance?
